ANGIODYNAMICS INC
Congressional Trades
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Debbie Wasserman SchultzHouse · D · FL |
ANGOANGIODYNAMICS INC · Stock |
Sale $2,000.00 |
Oct 24, 2025 | Oct 20, 2025 | Filing ↗ |
Debbie Wasserman SchultzHouse · D · FL |
ANGOANGIODYNAMICS INC · Stock |
Purchase $1,001 - $15,000 |
Jul 25, 2025 | Jun 27, 2025 | Filing ↗ |
Debbie Wasserman SchultzHouse · D · FL |
ANGOANGIODYNAMICS INC · Stock |
Sale $1,001 - $15,000 |
Jul 25, 2025 | Jul 16, 2025 | Filing ↗ |
Debbie Wasserman SchultzHouse · D · FL |
ANGOANGIODYNAMICS INC · Stock |
Sale $1,001 - $15,000 |
Dec 25, 2016 | Nov 8, 2016 | Filing ↗ |
Debbie Wasserman SchultzHouse · D · FL |
ANGOANGIODYNAMICS INC · Stock |
Purchase $1,001 - $15,000 |
Jul 6, 2016 | Apr 27, 2016 | Filing ↗ |
Debbie Wasserman SchultzHouse · D · FL |
ANGOANGIODYNAMICS INC · Stock |
Purchase $1,001 - $15,000 |
Jul 6, 2016 | Apr 27, 2016 | Filing ↗ |
Whale Activity
- Increased4
- New0
- Held0
- Decreased4
- Closed0
- No prior filing0
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 3.8M | $49.5M | increased |
| Point72 Asset Management, L.P. | 3.1M | $39.8M | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.7M | $22.0M | decreased |
| MILLENNIUM MANAGEMENT LLC | 783.1K | $10.2M | increased |
| RENAISSANCE TECHNOLOGIES LLC | 733.9K | $9.5M | decreased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 440.8K | $5.7M | increased |
| TWO SIGMA INVESTMENTS, LP | 306.3K | $4.0M | increased |
| CITADEL ADVISORS LLC | 12.5K | $162K | decreased |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Nighan Warren JRSVP Quality and Regulatory | Sale | −23.4K | $14.72 | $344K | Jul 30, 2026 | Form 4 ↗ |
| Weiss Lawrence TSVP, Chief Legal Officer | Purchase | +10.0K | $11.81 | $118K | Oct 21, 2025 | Form 4 ↗ |
| Trowbridge Stephen AEVP and CFO | Purchase | +890 | $11.16 | $10K | Oct 13, 2025 | Form 4 ↗ |
| Clemmer James CPresident and CEO · Director | Purchase | +10.0K | $11.15 | $112K | Oct 9, 2025 | Form 4 ↗ |
| Trowbridge Stephen AEVP and CFO | Tax withholding | −667 | $8.99 | $6K | Jul 21, 2025 | Form 4 ↗ |
| Nighan Warren JRSVP Quality and Regulatory | Tax withholding | −277 | $8.99 | $2K | Jul 21, 2025 | Form 4 ↗ |
| Campbell Chad ThomasSVP/GM, Vascular Access | Tax withholding | −395 | $8.99 | $4K | Jul 21, 2025 | Form 4 ↗ |
| Trowbridge Stephen AEVP and CFO | Tax withholding | −717 | $8.69 | $6K | Jul 20, 2025 | Form 4 ↗ |
| Piccinini LauraSVP International | Tax withholding | −616 | $8.69 | $5K | Jul 20, 2025 | Form 4 ↗ |
| Nighan Warren JRSVP Quality and Regulatory | Tax withholding | −251 | $8.69 | $2K | Jul 20, 2025 | Form 4 ↗ |
| Clemmer James CPresident and CEO · Director | Tax withholding | −3,673 | $8.99 | $33K | Jul 20, 2025 | Form 4 ↗ |
| Clemmer James CPresident and CEO · Director | Tax withholding | −2,982 | $8.69 | $26K | Jul 20, 2025 | Form 4 ↗ |
| Campbell Chad ThomasSVP/GM, Vascular Access | Tax withholding | −359 | $8.69 | $3K | Jul 20, 2025 | Form 4 ↗ |
| Trowbridge Stephen AEVP and CFO | Tax withholding | −2,585 | $8.69 | $22K | Jul 19, 2025 | Form 4 ↗ |
| Piccinini LauraSVP International | Tax withholding | −1,983 | $8.69 | $17K | Jul 19, 2025 | Form 4 ↗ |
| Nighan Warren JRSVP Quality and Regulatory | Tax withholding | −735 | $8.69 | $6K | Jul 19, 2025 | Form 4 ↗ |
| Clemmer James CPresident and CEO · Director | Tax withholding | −8,307 | $8.69 | $72K | Jul 19, 2025 | Form 4 ↗ |
| Clemmer James CPresident and CEO · Director | Tax withholding | −344 | $8.69 | $3K | Jul 19, 2025 | Form 4 ↗ |
| Campbell Chad ThomasSVP/GM, Vascular Access | Tax withholding | −1,025 | $8.69 | $9K | Jul 19, 2025 | Form 4 ↗ |
| Piccinini LauraSVP International | Tax withholding | −3,074 | $8.74 | $27K | Jul 17, 2025 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.2M | $15.3M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 973.1K | $12.7M | 0.02% | Jun 30, 2026 |
| Royce Small-Cap Opportunity Fund ROYCE FUND | 707.4K | $9.2M | 0.65% | Jun 30, 2026 |
| College Retirement Equities Fund - Total Global Stock Account College Retirement Equities Fund | 626.5K | $8.2M | 0.01% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 484.8K | $6.3M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 406.7K | $6.0M | 0.02% | Jul 31, 2026 |
| Nuveen Quant Small Cap Equity Fund TIAA-CREF Funds | 382.5K | $5.7M | 0.14% | Jul 31, 2026 |
| First Eagle Small Cap Opportunity Fund First Eagle Funds | 310.7K | $4.6M | 0.16% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF SPDR SERIES TRUST | 336.0K | $3.8M | 0.16% | Mar 31, 2026 |
| ROYCE MICRO-CAP TRUST, INC. | 283.9K | $3.7M | 0.41% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list ANGO's shares (CUSIP 03475V101), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Corporate Lobbying
No lobbying filings found naming ANGIODYNAMICS INC as the client.
Government Contracts
No federal contract awards found for ANGIODYNAMICS INC.
U.S. Patents
No USPTO patent applications found for ANGIODYNAMICS INC.
Annual Financials
No annual XBRL figures on record for ANGO. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
No stock splits in ANGO's price history.
Material Events (8-K)
- 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureJul 14, 2026
EDGAR ↗
About ANGIODYNAMICS INC
. OVERVIEW AngioDynamics is a dynamic, diversified medical technology company committed to expanding treatment options and improving patient outcomes and quality of life by designing, manufacturing and selling products and technologies which aid clinicians in the treatment of patients with cardiovascular disease and cancer diagnoses. Our execution strategy is built on innovative R&D, clinical and regulatory pathway expansion and customer centric sales performance. HISTORY AngioDynamics was founded in Queensbury, N.Y., U.S., in 1988 and began manufacturing and shipping product in the early 1990s. The Company is headquartered in Latham, N.Y., with manufacturing primarily out of the Queensbury…

